Sökresultat - Daniel I. Rosenthal

  • Visas 1 - 7 av 7 resultat
Förfina resultatet
  1. 1
    Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy

    Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy av Jeannie S. Huang, Petra Rietschel, Colleen Hadigan, Daniel I. Rosenthal, Steven Grinspoon

    Publicerad 2001
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  2. 2
    Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

    Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. av Laurence Katznelson, Joel S. Finkelstein, David Schoenfeld, Daniel I. Rosenthal, Edward Anderson, Anne Klibanski

    Publicerad 1996
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Clinical and Biochemical Manifestations of Hyaluronidase Deficiency

    Clinical and Biochemical Manifestations of Hyaluronidase Deficiency av Marvin R. Natowicz, M. Priscilla Short, Yu Wang, G. Richard Dickersin, Mark C. Gebhardt, Daniel I. Rosenthal, Katherine B. Sims, Andrew E. Rosenberg

    Publicerad 1996
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study

    Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study av KB Sims, GM Pastores, NJ Weinreb, J. A. Barranger, BE Rosenbloom, Seymour Packman, Paige Kaplan, Henry J. Mankin, Ramnik J. Xavier, Jennifer Angell, MA Fitzpatrick, Daniel I. Rosenthal

    Publicerad 2008
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat

    Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat av Ravi S. Kamath, Elena Lukina, Nora Watman, Marta Dragosky, Gregory M. Pastores, Elsa Ávila Arreguin, Hanna Rosenbaum, Ari Zimran, Rasha Aguzzi, Ana Cristina Puga, Andrea M. Norfleet, Michel Peterschmitt, Daniel I. Rosenthal

    Publicerad 2014
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study

    Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 stu... av Elena Lukina, Nora Watman, Elsa Ávila Arreguin, Marta Dragosky, Marcelo Iastrebner, Hanna Rosenbaum, Mici Phillips, Gregory M. Pastores, Ravi S. Kamath, Daniel I. Rosenthal, Mathilde Kaper, Tejdip Singh, Ana Cristina Puga, Michel Peterschmitt

    Publicerad 2010
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1

    A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1 av Elena Lukina, Nora Watman, Elsa Ávila Arreguin, Maryam Banikazemi, Marta Dragosky, Marcelo Iastrebner, Hanna Rosenbaum, Mici Phillips, Gregory M. Pastores, Daniel I. Rosenthal, Mathilde Kaper, Tejdip Singh, Ana Cristina Puga, Peter L. Bonate, Michel Peterschmitt

    Publicerad 2010
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: